Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 16/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14529821 | 0.88 | OPRD1 (0.70) | OPRD1KCNH2CHRM4HSD11B1 | |
| SCHEMBL14530257 | 0.86 | OPRD1 (0.78) | OPRD1KCNH2HSD11B1 | |
| SCHEMBL5314036 | 0.84 | OPRD1 (0.70) | OPRD1KCNH2HSD11B1 | |
| SCHEMBL5316820 | 0.84 | OPRD1 (0.78) | OPRD1KCNH2HSD11B1 | |
| SCHEMBL5316545 | 0.83 | OPRD1 (0.68) | OPRD1KCNH2 | |
| SCHEMBL14530107 | 0.82 | OPRD1 (0.76) | OPRD1KCNH2HSD11B1 | |
| SCHEMBL5313435 | 0.81 | OPRD1 (0.83) | OPRD1KCNH2HSD11B1 | |
| SCHEMBL5312960 | 0.81 | OPRD1 (1.00) | OPRD1KCNH2HSD11B1 | |
| SCHEMBL5315770 | 0.81 | OPRD1 (0.73) | OPRD1KCNH2HSD11B1 | |
| SCHEMBL5315773 | 0.81 | OPRD1 (0.73) | OPRD1KCNH2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007057775-A1 | SPIROPIPERIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| WO-2007057775-A1 | SPIROPIPERIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |